aspirin has been researched along with e 5555 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Bhatt, DL; Dastros-Pitei, D; Flather, M; Kogushi, M; Serebruany, VL | 1 |
| Pollack, CV | 1 |
| Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD; Ueno, M | 1 |
| Leonardi, S; Mahaffey, KW; Tricoci, P | 1 |
| Augustine, TN; Xulu, KR | 1 |
3 review(s) available for aspirin and e 5555
| Article | Year |
|---|---|
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Antiplatelet therapy: thrombin receptor antagonists.
Topics: Aspirin; Blood Platelets; Humans; Imines; Lactones; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thrombin; Thrombosis | 2011 |
Promises of PAR-1 inhibition in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Imines; Lactones; Male; Myocardial Ischemia; Platelet Activation; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, PAR-1; Recurrence; Treatment Outcome | 2012 |
3 other study(ies) available for aspirin and e 5555
| Article | Year |
|---|---|
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Synergism; Female; Flow Cytometry; Humans; Imines; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Receptor, PAR-1; Thrombosis; Ticlopidine | 2009 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aspirin; Blood Coagulation; Breast Neoplasms; Cells, Cultured; Clopidogrel; Drug Interactions; Epithelial-Mesenchymal Transition; Female; Humans; Imines; MCF-7 Cells; Platelet Aggregation Inhibitors; Pyridines; Thrombin; Thrombophilia | 2021 |